EHVA launches a clinical trial to test a combination of therapeutic vaccines and an immunotherapy drug!
EHVA (European HIV Vaccine Alliance) announces the start of the EHVA T01 / ANRS VRI05 trial.
EHVA-T01 / ANRS VRI05, a double-blind, randomized, Phase I/II trial, will evaluate the combination of experimental HIV therapeutic vaccines and an investigational immunotherapy drug in people living with HIV in six European countries – France, Germany, Spain, Italy, the United Kingdom and Switzerland.
The initiation of the selection of participants will start at the University Hospital of Lausanne in Switzerland and will then be followed in the other countries.
Professor Yves Lévy is the coordinating investigator of EHVA-T01/ANRS VRI05, an Inserm-ANRS promoted trial managed by the Clinical Trial Unit of the Medical Research Council of University College London.
Professor Yves Lévy, Director of the VRI (Vaccine Research Institute), is the coordinator of the EHVA consortium, a 5-year project funded by the European Union’s Horizon 2020 research and innovation programme to promote the development of an effective HIV vaccine (www.ehv-a.eu). EHVA has 39 partners, each with the expertise to promote a comprehensive approach to the development of an effective HIV vaccine.
POSTPONED: Upcoming title :
«POSTPONED : Ilaria Cascone - 12h – 12h – Amphi 5, 4ème étage de la Faculté de Santé de Créteil»
POSTPONED : Pending title :
«POSTPONED : Sophie Vaulont - 12h – Amphi 5, 4ème étage de la Faculté de Médecine de Créteil»
REPORTE A UNE DATE ULTERIEURE : TAK1 signalling in MSC regulates Th2 inflammation :
«REPORTE A UNE DATE ULTERIEURE : Marine Theret - 12h – Amphi 4, Rdc de la Faculté de Santé de Créteil»
All incoming seminars